Skip to main content

Marizyme

  • About
      • Back
      • Overview
      • Executive Management
      • Board of Directors
      • Corporate Governance
  • Products
      • Back
      • Overview
      • DuraGraft®
      • Krillase®
      • MATLOC™ Platform
  • Clinical
      • Back
      • Publications
      • DuraGraft Publications
      • MATLOC Publications
  • Investors
  • Contact
      • Back
      • Contact Us
  • Sign Up
  • Language
      • Back
      • GER
adobe stock 229690447 preview

NEWS
2022

  • 2023
  • 2022
  • 2021
List of articles in category 2022 News
Title
05.01.2022
Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office

imgfooter

Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes.

 

Investors

  • Back
  • Stock Info
  • SEC Filings
  • Corporate Governance

Contact

  • Back
  • Contact Us
  • Sign Up
 

Get In Touch 

noun map 223137 555 Heritage Drive, Ste. 205,
Jupiter, FL 33458
noun phone 4637987 (561) 935-9955
noun email 3083073 info@marizyme.com 
Marizyme
© Copyright - 2023 Marizyme Inc. | All Rights Reserved | Website by Sandman Media Inc